They were divided up into two groups of 49; the first group consisted of patients to be treated with a drug called Tamoxifen and the other 49 were treated with Tamoxifen and the anabolic steroid known as Nandrolone Decanoate, or its brand name, Deca Durabolin. Buy Deca Durabolin online here.
Table of Contents
This trial involved the analytical comparison of the 49 advanced-stage breast cancer patients being treated with Tamoxifen only and the 49 advanced-stage breast cancer patients who were treated with the combination of Tamoxifen and Nandrolone Decanoate. The first group of 49, after an unspecified amount of time being treated by Tamoxifen, had a measured response rate to this medicine at 49 percent.
The second 49 women in the study who were being treated with the combination of Tamoxifen and Nandrolone Decanoate had a response rate of only 45 percent, a bit lower than with Tamoxifen alone.
The determinate analysis indicated that each group’s response to treatment was not that much different between the two groups. Each of the 98 patients suffered no significant Nandrolone Decanoate side effects and was tolerant of the drugs given to them for treatment.
Although the side effects from taking one or both of the pharmaceutical drugs were well tolerated by the 98 advanced-stage breast cancer patients, this does not mean that there were absolutely no side effects from being exposed to the drugs and their potential for negative results.
It just warrants the indications that what side effects were experienced by these patients, whether taking Tamoxifen or a combination of Tamoxifen and the anabolic steroid, Deca Durabolin, were mild at their worst and did not require any of the 98 total patients to be withdrawn from the study.
Tamoxifen, a common pharmaceutical drug used to treat some forms of breast carcinoma, or what is more commonly known as cancer, gynecomastia in men (enlargement of breast tissue) and breast or pancreatic neoplasm, has two brand names associated with it, one of which is Nolvadex, while the other is Soltamox. Tamoxifen is used primarily by oncologists in its estrogen antagonist form (as opposed to its other formulated design as an estrogen agonist).
Nandrolone Decanoate, or what is usually referred by as the official brand name, Deca Durabolin, and also what is known in the athletic and bodybuilder universe as simply “Deca,” does come with some risk as an injection and even holds some risk of side effects when administered as an oral form, or capsule. Check out the best cutting cycles here.
When added at the recommended dosage with Tamoxifen at its recommended dosage, the two medicines did not seem to counteract with each other in their corresponding acts of treatment for advanced breast cancer or in any noticeable side effects.
Some potential, yet rarely reported side effects with the drug, Tamoxifen, are vaginal bleeding; swelling of hands, feet and legs; nausea; and additional forming of breast lumps. These, and other related side effects from the drug, are all due to the medicine’s baseline usage for the blocking the female hormone, estrogen and some of the negative effects excess estrogen can have on the body, such as breast cancer.
On the other hand, Nandrolone Decanoate has a greater potential for negative side effects to be experienced by users and medical patients alike, especially in women who expose themselves to the drug for whatever reason, whether for medical purposes or recreational, such as with athletes.
Women who take the drug, which is a derivative of 19-nor testosterone, increase their risk of developing virile side effects such as a deepening of the voice, body hair growth and excess facial hair growth. That’s why women are better off trying Winstrol for lower side effects because the risks are too high with Deca.
A 2005 medical trial study involving nine men with the HIV virus consisted of orally administering 400 mg of Megestrol Acetate once per day along with 100 mg of Nandrolone Decanoate via intramuscular injection once every 15 days during a 16-week cycle. Before, during and after the trial study, the nine HIV-infected men were analyzed for fat mass, muscle strength, circumference of upper arms, and measurement of skin folds.
Because of the data collected before and during the 16-week study, it was determined that the men had significantly increased in body weight and muscle strength with only a few having experienced noticeable side effects.
Some of the side effects included one mild case of Gynecomastia, or breast tissue enlargement, four cases of asymptomatic adrenal suppression, and while all experienced a lowering of testosterone serum levels, only four experienced levels that fell below normal levels.
In Sydney, Australia, a 16-week trial study was held by several HIV/AIDS ambulatory specialists within private and public sectors of the industry. Of 220 pre-study phase applicants, 24 men infected with HIV/AIDS, 11 percent of the 220, had gone on to officially participate in the trial study due to weight-gain failure during the pre-study phase. Seventeen of the 24 men in the study actually completed the 16 weeks after being injected intramuscularly once every two weeks by professional administers.
The study, in the end, had determined the conclusion and beneficial price that the use of Nandrolone Decanoate had on the patients for wasting associated with the HIV virus. It was significantly beneficial to those suffering from body wasting from the virus. These injections added much needed lean body mass and greatly improved the body’s functioning.
Overall, the medical use of this controversial anabolic steroid, Nandrolone Decanoate or Deca Durabolin, provides conclusive evidence for the significant improvement of quality of life in patients suffering from degenerative body and bone mass issues due to disease and postmenopausal related symptoms.